Vertex Pharmaceuticals Payments to Acquire Debt Securities, Available-for-Sale increased by 103.8% to $2.51B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 52.2%, from $1.65B to $2.51B. Over 4 years (FY 2021 to FY 2025), Payments to Acquire Debt Securities, Available-for-Sale shows an upward trend with a 86.5% CAGR.
Higher outflows indicate active investment in fixed-income assets, often driven by premium growth or capital deployment strategies.
Represents the cash outflows used to purchase debt securities classified as available-for-sale. This reflects the compan...
Standard for institutional investors and insurance companies managing float.
other_payments_to_acquire_available_for_sale_securities_debt| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $118.00M | $208.30M | $80.40M | $117.10M | $110.80M | $189.90M | $274.90M | $946.63M | $946.63M | $946.63M | $946.63M | $2.60B | $1.30B | $1.38B | $2.16B | $1.65B | $2.17B | $1.35B | $1.23B | $2.51B |
| QoQ Change | — | +76.5% | -61.4% | +45.6% | -5.4% | +71.4% | +44.8% | +244.4% | +0.0% | +0.0% | +0.0% | +174.5% | -50.1% | +6.8% | +55.9% | -23.7% | +31.9% | -38.1% | -8.5% | +103.8% |
| YoY Change | — | — | — | — | -6.1% | -8.8% | +241.9% | +708.4% | +754.4% | +398.5% | +244.4% | +174.5% | +37.0% | +46.3% | +128.0% | -36.6% | +67.6% | -2.8% | -43.0% | +52.2% |